(Q34926489)

5 August 2017

1 reference

title

Translational toxicology and the work of the predictive safety testing consortium (English)

1 reference

5 August 2017

W B Mattes

1

1 reference

5 August 2017

E G Walker

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

21 January 2009

1 reference

Clinical Pharmacology & Therapeutics

5 August 2017

published in

1 reference

5 August 2017

volume

85

1 reference

5 August 2017

issue

3

1 reference

5 August 2017

page(s)

327-330

1 reference

Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.270

Safety evaluation to support First-In-Man investigations II: toxicology studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.270

Can the pharmaceutical industry reduce attrition rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.270

Concordance of the toxicity of pharmaceuticals in humans and in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.270

Novel technologies for the discovery and quantitation of biomarkers of toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.270

New technologies around biomarkers and their interplay with drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.270

Strategic paths for biomarker qualification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.270

Public consortium efforts in toxicogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.270

Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.270

The clinical and renal consequences of contrast-induced nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.270

A meeting of minds: interdisciplinary research in the health sciences in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.270

Biomedical imaging in the safety evaluation of new drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.270

Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.270

7 January 2021

A prototypical process for creating evidentiary standards for biomarkers and diagnostics

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.270

7 January 2021

Drug Development and the FDA's Critical Path Initiative

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.270

7 January 2021

Best practices guideline: toxicologic histopathology

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.270

7 January 2021

The future of interdisciplinary research and training: how to conquer the silo guardians

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.270

7 January 2021

Translational research in the pharmaceutical industry: from bench to bedside

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.270

7 January 2021

An assessment of statin safety by hepatologists

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.270

7 January 2021

Industry's challenge to academia: changing the bench to bedside paradigm

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.270

7 January 2021

Identifiers

DOI

10.1038/CLPT.2008.270

1 reference

Dimensions Publication ID

5 August 2017

1018827438

0 references

1 reference